Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases

Liver International

Volumn 31, Issue 7, 2011, Pages 985-993

  Völzke, Henry ^a   Alte, Dietrich ^a   Ittermann, Till ^a   Schmidt, Carsten O ^a   Rettig, Rainer ^a   Mayerle, Julia ^a   Lowenfels, Albert B ^b   Lerch, Markus M ^a   Nauck, Matthias ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Epidemiology; Hepatic steatosis; Population; Reference intervals

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; MALE; PHOTOMETRY; REFERENCE VALUE;

ADULT; AGE FACTORS; AGED; FATTY LIVER; FEMALE; GERMANY; HUMANS; LIVER DISEASES; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; REFERENCE VALUES; TRANSAMINASES;

EID: 79960105143     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02371.x     Document Type: Article

References (42)

1. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
2. Mohamadnejad M, Pourshams A, Malekzadeh R, et al. Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors. World J Gastroenterol 2003; 9: 2322-4.
3. Lozano M, Cid J, Bedini JL, et al. Study of serum alanine-aminotransferase levels in blood donors in Spain. Haematologica 1998; 83: 237-9.
4. Gillespie TW, Hillyer CD. Blood donors and factors impacting the blood donation decision. Transfus Med Rev 2002; 16: 115-30.
5. Kaplan MM. Alanine aminotransferase levels: what's normal? Ann Intern Med 2002; 137: 49-51.
6. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650-6.
7. Volzke H, Alte D, Kohlmann T, et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid 2005; 15: 279-85.
8. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991; 43: 26-31.
9. Völzke H, Alte D, Schmidt CO. Cohort profile: the study of health in Pomerania. Int J Epidemio 2011; 40: 294-307.
10. Volzke H, Robinson DM, Schminke U, et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004; 89: 2145-9.
11. Alte D, Luedemann J, Rose HJ, John U. Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004; 28: 931-40.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
13. Rosalki SB. Carbohydrate-deficient transferrin: a marker of alcohol abuse. Int J Clin Pract 2004; 58: 391-3.
14. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11: 1848-53.
15. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
16. Volzke H, Schwarz S, Baumeister SE, et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007; 56: 594-5.
17. Dorr M, Wolff B, Robinson DM, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90: 673-7.
18. Ludemann J, Piek M, Wood WG, et al. Methods for quality assurance of medical examination in epidemiological field studies: the 'Study of Health in Pomerania' (SHIP). Gesundheitswesen 2000; 62: 234-43.
19. Kariv R, Leshno M, Beth-Or A, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006; 26: 445-50.
20. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 2007; 53: 686-92.
21. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21: 71-80.
22. Leclercq I, Horsmans Y, De Bruyere M, Geubel AP. Influence of body mass index, sex and age on serum alanine aminotransferase (ALT) level in healthy blood donors. Acta Gastroenterol Belg 1999; 62: 16-20.
23. Samadi N, Cembrowski GS, Chan J. Effect of waist circumference on reference intervals of liver-related enzyme tests in apparently healthy adult Mexican Americans, black and white Americans. Clin Biochem 2007; 40: 206-12.
24. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007; 25: 207-18.
25. Friedrich-Rust M, Zeuzem S. Reproducibility and limitations of transient elastography. Liver Int 29: 619-20.
26. Cotler SJ, Guzman G, Layden-Almer J, et al. Measurement of liver fat content using selective saturation at 3.0 T. J Magn Reson Imaging 2007; 25: 743-8.
27. Pacifico L, Celestre M, Anania C, et al. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr 2007; 96: 542-7.
28. Yue M, Ni Q, Yu CH, et al. Transient elevation of hepatic enzymes in volunteers after intake of alcohol. Hepatobiliary Pancreat Dis Int 2006; 5: 52-5.
29. Helander A, Vabo E, Levin K, Borg S. Intra- and interindividual variability of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume in teetotalers. Clin Chem 1998; 44: 2120-5.
30. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
31. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732-7.
32. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005; 258: 527-35.
33. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623-32.
34. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation 2005; 112: 2130-7.
35. Meisinger C, Doring A, Schneider A, Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006; 189: 297-302.
36. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007; 53: 71-7.
37. Lee DH, Ha MH, Kam S, et al. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am J Epidemiol 2006; 163: 57-65.
38. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101: 76-82.
39. Meisinger C, Heier M, Volzke H, et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24: 293-9.
40. Volzke H, Baumeister SE, Alte D, et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence. Digestion 2005; 71: 97-105.
41. Baumeister SE, Alte D, Meyer C, John U. Health risk drinking and problematic consumption of alcohol in pomerania: comparative analysis of the study of health in pomerania (SHIP) compared with the federal German health and examination survey in 1998. Gesundheitswesen 2005; 67: 39-47.
42. Rehm J, Greenfield TK, Walsh G, et al. Assessment methods for alcohol consumption, prevalence of high risk drinking and harm: a sensitivity analysis. Int J Epidemiol 1999; 28: 219-24.